A Drug's Safety Profile is the Leading Attribute in Antibiotic Selection, According to a New Report from AMR and Decision Resources
MALVERN, Pa. and WALTHAM, Mass., April 21 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that in addition to surveyed infectious disease specialists' prediction that empiric coverage of methicillin-resistant Staphylococcus aureus (MRSA) will increase, they foresee greater use of parenteral outpatient therapy (intravenous or intramuscular injection) for the treatment of osteomyelitis. Osteomyelitis is an infection of bone or bone marrow caused by bacterial infections.
"Osteomyelitis often requires an extended duration of antibiotic therapy after hospital discharge and many patients are prescribed an injectable agent," stated Lisa Arias, analyst at Decision Resources. "Nearly one-third of surveyed physicians expect increased use of parenteral antibiotic therapy in the next five years."
The new report entitled Hospital Anti-Infectives Insight Series: Osteomyelitis also finds that although surveyed infectious disease specialists look for a range of attributes when prescribing an antibiotic for osteomyelitis, the leading attribute, by far, is the drug's safety profile when administered over a long period of time -- 77 percent of surveyed physicians cited this attribute as extremely important. Physicians also look for an antibiotic that can be dosed, administered and monitored easily in the outpatient setting. Other important factors are the drug's ability to penetrate bone and activity against MRSA.
About Hospital Anti-Infectives Insight Series
AMR and Decision Resources' Hospital Anti-Infectives Insight Series analyzes hospital antibiotic prescribing patterns using AMR's comprehensive and highly detailed clinical data in conjunction with Decision Resources' disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. These reports examine the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.
AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.
About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 firstname.lastname@example.org email@example.com
|SOURCE Decision Resources; Arlington Medical Resources|
Copyright©2009 PR Newswire.
All rights reserved